FilingSEC EDGAR8-K
iBio Highlights Preclinical Data for Obesity Candidate IBIO-610
· SEC accepted
StagePreclinical
Filing content
The company reported muscle preservation data from an obese NHP study for IBIO-610 in combination with semaglutide and plans to initiate first-in-human trials in the first half of 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…